Alpha 2.0
Login Register
» Authors » Jan Paul de Boer

Jan Paul de Boer

Explore the profile of Jan Paul de Boer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2185
Followers 0
Related Specialties
Oncology
General Surgery
Radiology
Top 10 Co-Authors
Flora E van Leeuwen
Charlotte L Zuur
Daphne de Jong
Alfons J M Balm
Abrahim Al-Mamgani
Berthe M P Aleman
Michael Hauptmann
Coen R N Rasch
Pieternella J Lugtenburg
Arash Navran
Published In
Head Neck
Blood
Radiother Oncol
J Clin Oncol
Nat Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Effect of hydration schedules on dose-limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin
Schaeffers A, van Neerven C, van Balen D, Crul M, Slingerland M, Luelmo S, et al.
Br J Clin Pharmacol . 2025 Feb; PMID: 39989079
Aims: The aim of this study was to determine if head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin chemoradiotherapy and short hydration (SH) experience less dose-limiting toxicity...
2.
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma
Meertens M, Giraud E, Hassan E, Zielhuis S, Snels T, Desar I, et al.
Cancer Chemother Pharmacol . 2025 Jan; 95(1):25. PMID: 39820703
Purpose: After initial approval of lenvatinib for radioiodine-refractory differentiated thyroid cancer (DTC), it has also shown promising outcomes in among others metastatic renal cell carcinoma (mRCC). Given that trial populations...
3.
The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma
Schaeffers A, Burger A, Duinkerken C, van Sluis K, de Boer J, van der Molen L, et al.
Head Neck . 2024 Aug; 47(1):189-200. PMID: 39096016
Introduction: Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin-based chemoradiotherapy (CRT) frequently experience irreversible sensorineural hearing loss (SNHL). Patients with low lumbar skeletal muscle index (LSMI)...
4.
FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection
Navran A, Kayembe M, Gouw Z, Vogel W, Karssemakers L, de Boer J, et al.
Radiother Oncol . 2024 Jun; 198:110407. PMID: 38942119
Purpose: In the last decades FDG-PET/CT is increasingly used in combination with the standard diagnostic modalities (MRI + US-FNA) to identify residual neck disease (RND) after (chemo)radiotherapy for head-and-neck squamous...
5.
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol
Schaeffers A, Devriese L, van Gils C, Dankbaar J, Voortman J, de Boer J, et al.
PLoS One . 2023 Nov; 18(11):e0294147. PMID: 38011186
Chemoradiotherapy with cisplatin in a triweekly regimen of 100 mg/m2 body surface area, is used to treat locally advanced head and neck squamous cell carcinoma (HNSCC) with curative intent. Cisplatin...
6.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Ansell S, Brockelmann P, von Keudell G, Lee H, Santoro A, Zinzani P, et al.
Blood Adv . 2023 Aug; 7(20):6266-6274. PMID: 37530622
Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205...
7.
Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study
Mols F, Schoormans D, Netea-Maier R, Husson O, Beijer S, Van Deun K, et al.
Thyroid Res . 2023 Jul; 16(1):23. PMID: 37424010
Background: Thyroid cancer (TC) patients are understudied but appear to be at risk for poor physical and psychosocial outcomes. Knowledge of the course and determinants of these deteriorated outcomes is...
8.
Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer
Donswijk M, Piek M, Cheung Z, Wondergem M, Stokkel M, de Boer J, et al.
Eur Radiol . 2023 Mar; 33(5):3377-3385. PMID: 36892644
Objective: To investigate the incidences of prostate-specific membrane antigen (PSMA) thyroid incidentaloma (PTI) using different methods to define PTI, to compare the incidence of PTI among different PSMA PET tracers,...
9.
Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy
Ykema B, Gini A, Rigter L, Spaander M, Moons L, Bisseling T, et al.
Cancer Epidemiol Biomarkers Prev . 2022 Sep; 31(12):2157-2168. PMID: 36166472
Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin...
10.
The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice
Piek M, de Boer J, Van Duijnhoven F, van der Wal J, Vriens M, van Leeuwaarde R, et al.
BMC Cancer . 2022 Sep; 22(1):1018. PMID: 36163009
Background: Breast cancer (BC) and differentiated thyroid cancer (TC) are two common cancer types with the highest incidence in women. BC and TC can develop synchronous or metachronous and the...